CardioMetabolics

CardioMetabolics was a Canadian biopharmaceutical company that later changed its name to Valens Pharma Ltd. The company focused on metabolic modulation using dichloroacetate and related compounds, positioning these agents as pyruvate dehydrogenase kinase blockers that shift cellular energy metabolism toward glucose oxidation. Its lead program was an intravenous formulation of dichloroacetate evaluated in a Phase 2 study in high-risk geriatric patients undergoing open heart surgery. Public reports indicate the company suspended work on the DCA i.v. program after reviewing Phase 2 data, but the legal entity appears to have remained active in Alberta. The company was privately held and based in Edmonton, Alberta.